Breast Cancer
Conditions
Keywords
male, breast cancer
Brief summary
Rationale: Gathering medical information and tumor samples from patients with male breast cancer may help doctors learn more about the disease. Purpose retrospective part: to perform a large international retrospective analysis of clinical and biological data of male BC patients treated in the participating centers from 1990 to 2010. Purpose prospective part: to create a registry of men with breast cancer for a period of 30 months (starting early 2014).
Detailed description
Objectives retrospective part (closed to patients registration in September 2013): * To perform a large international joint retrospective analysis of clinical and biological data of male breast cancer (BC) patients treated from 1990 to 2010. * To create a database of patient characteristics, disease features, treatments received, and clinical outcomes of a large series of men diagnosed with BC from 1990 to 2010 in centers in Europe and USA. * To perform a central pathological review of the corresponding large series of male BC tumors to determine their biologic characteristics and identify relevant prognostic and predictive markers. Objectives prospective part (opened early 2014): * To run a prospective registry of all male BC patients (including newly diagnosed) irrespective of the stage and treatment, in the participating institutions for a period of 30 months; collection of FFPE, fresh frozen and blood samples is optional but highly encouraged. * Quality of Life sub-study The two parts of this study will provide important information regarding male BC biology and clinical evolution. The collected follow-up information will provide an overview of the current practice in the early and the advanced disease and also offer precious information of the disease evolution in such rare patients' population.
Interventions
None listed
Sponsors
European Organisation for Research and Treatment of Cancer - EORTC
Breast International Group
Swiss Cancer Institute
Cancer Trials Ireland
Borstkanker Onderzoek Groep
Swedish Association of Breast Oncologists
Hellenic Cooperative Oncology Group
Hellenic Oncology Research Group
Latin American Cooperative Oncology Group
Translational Breast Cancer Research Consortium
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Retrospective part (closed to patients registration): * Men with histologically proven invasive breast carcinoma diagnosed since 1990 to 2010. * A FFPE tissue sample from the primary tumor (e.g. biopsy or surgery) is mandatory Prospective part: * All men, with histologically proven invasive breast cancer, newly presenting at the center irrespective of the stage of disease, initial diagnosis date or treatment received. * patients cannot be registered in both the retrospective and protective parts of the study * patients who newly present at the center in the 3 months prior to center activation are still eligible as long as they were not previously included in the retrospective part of the study * Before patient registration, written informed consent must be obtained according to ICH/GCP, and national/local regulations. * Collection of left-over FFPE and frozen tumor samples as well as blood is optional. Both parts: * Concomitant DCIS or LCIS are allowed only if invasive cancer is present. * Patients should be 18 years or over at the time of diagnosis. * The study will accept all stages of disease (e.g. early BC, locally advanced and metastatic disease) independent of the treatment received. Patients with past or concurrent other malignancies are eligible.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical outcomes: survival, progression free survival, time to locoregional relapse, time to distant relapse, time to second primary. | end of study |
| Patient and disease characteristics. | end of study |
| Patterns of treatment offered to these patients | end of study |
| Biological characterization of the disease | End of study |
Countries
Belgium, Brazil, Egypt, Greece, Ireland, Mexico, Netherlands, Peru, Poland, Portugal, Serbia, Spain, Sweden, Switzerland, United Kingdom, United States
Contacts
STUDY_CHAIRFatima Cardoso, MD
Champalimaud Cancer Center (Portugal)
STUDY_CHAIRSharon H. Giordano, MD, MPH
M. D. Anderson Cancer Center (TX, USA)
Outcome results
None listed